Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors.
暂无分享,去创建一个
M. Konopleva | H. Kantarjian | S. Verstovsek | K. Patel | E. Jabbour | N. Daver | C. Dinardo | L. Masarová | Y. Alvarado | M. Alfayez | H. Chifotides